HAYWARD, Calif.–(BUSINESS WIRE)–Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, international biopharmaceutical firm targeted on creating differentiated molecules and mixture therapies for sufferers with most cancers, in the present day introduced that the Compensation Committee of the Firm’s Board of Administrators granted 4 new staff choices to buy a complete of 66,900 shares of the Firm’s widespread inventory at an train value per share of $15.96, which was the closing value on December 23, 2024, and restricted inventory items to accumulate a complete of 33,450 shares of the Firm’s widespread inventory. The fairness awards had been granted pursuant to the Firm’s 2020 Inducement Plan, which was authorised by the Firm’s Board of Administrators in January 2020 pursuant to the inducement exception underneath NYSE Listed Firm Guide Rule 303A.08.
About Arcus Biosciences (NYSE:)
Arcus Biosciences is a clinical-stage, international biopharmaceutical firm creating differentiated molecules and mixture medicines for individuals with most cancers. In partnership with business collaborators, sufferers and physicians world wide, Arcus is expediting the event of first- or best-in-class medicines towards well-characterized organic targets and pathways and finding out novel, biology-driven combos which have the potential to assist individuals with most cancers dwell longer. Based in 2015, the corporate has expedited the event of a number of investigational medicines into medical research, together with new mixture approaches that concentrate on TIGIT, PD-1, HIF-2a, CD73, twin A2a/A2b receptor, CD39 and AXL. For extra details about Arcus Biosciences’ medical and preclinical applications, please go to www.arcusbio.com.
Inducement PR
Supply: Arcus Biosciences
View supply model on businesswire.com: https://www.businesswire.com/information/house/20241224871937/en/
Investor Inquiries:
Pia Eaves
VP of Investor Relations & Technique
(617) 459-2006
[email protected]
Media Inquiries:
Holli Kolkey
VP of Company Communications
(650) 922-1269
[email protected]
Supply: Arcus Biosciences
